Loading patent…
AssigneesNovozymes A/S, Novozymes, Inc.
InventorsAllan Svendsen, Michael Skjoet, Debbie Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
Estimating the term…
The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
An isolated variant lipase which
An isolated variant lipase which
Dependencies are inferred from the claim text.